Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 7 (8), 694-710

The Nociceptin/Orphanin FQ Receptor: A Target With Broad Therapeutic Potential

Affiliations

The Nociceptin/Orphanin FQ Receptor: A Target With Broad Therapeutic Potential

David G Lambert. Nat Rev Drug Discov.

Abstract

Identification of the enigmatic nociceptin/orphanin FQ peptide (N/OFQ) in 1995 represented the first successful use of reverse pharmacology and led to deorphanization of the N/OFQ receptor (NOP). Subsequently, the N/OFQ-NOP system has been implicated in a wide range of biological functions, including pain, drug abuse, cardiovascular control and immunity. Although this could be considered a hurdle for the development of pharmaceuticals selective for a specific disease indication, NOP represents a viable drug target. This article describes potential clinical indications and highlights the current status of the very limited number of clinical trials.

Similar articles

See all similar articles

Cited by 104 PubMed Central articles

See all "Cited by" articles

Publication types

LinkOut - more resources

Feedback